Switching to Tenecteplase from Alteplase for Ischemic Stroke: Is it the Time for Universal Adoption?
- PMID: 37064286
- PMCID: PMC10101158
- DOI: 10.1177/09727531221125589
Switching to Tenecteplase from Alteplase for Ischemic Stroke: Is it the Time for Universal Adoption?
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
References
-
- Coutts SB, Yu AYX.. Tenecteplase for acute stroke: the thrombolysis puzzle. The Lancet Neurology 2022; 21(6): 496–497. - PubMed
-
- Burgos AM, Saver JL.. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke. Stroke 2019; 50(8): 2156–2162. - PubMed
-
- Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischemic stroke in Canada (AcT): A pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. The Lancet 2022; 400(10347):161–169. - PubMed
-
- Katsanos AH, Safouris A, Sarraj A, Magoufis G, Leker RR, Khatri P, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions. Stroke 2021; 52(1): 308–312. - PubMed
